Use of NQO1 status as a selective biomarker for oesophageal squamous cell carcinomas with greater sensitivity to 17-AAG

BMC Cancer

Volumn 14, Issue 1, 2014, Pages

  Hadley, Katie E ^a   Hendricks, Denver T ^a  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA; OXIDOREDUCTASE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE QUINONE OXIDOREDUCTASE 1; TANESPIMYCIN; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; BENZOQUINONE DERIVATIVE; HEAT SHOCK PROTEIN 90; MACROCYCLIC LACTAM; NQO1 PROTEIN, HUMAN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE); TUMOR MARKER;

ALLELE; ARTICLE; CONTROLLED STUDY; DRUG POTENCY; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; FIBROBLAST; HUMAN; HUMAN CELL; MTT ASSAY; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; SINGLE NUCLEOTIDE POLYMORPHISM; SQUAMOUS CELL CARCINOMA CELL LINE; WESTERN BLOTTING; ANTAGONISTS AND INHIBITORS; CELL PROLIFERATION; DOSE RESPONSE; DRUG EFFECTS; ENZYMOLOGY; ESOPHAGUS TUMOR; GENETIC TRANSFECTION; GENETICS; METABOLISM; PATHOLOGY; PATIENT SELECTION; PHARMACOGENETICS; SQUAMOUS CELL CARCINOMA; TIME; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; BENZOQUINONES; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; ESOPHAGEAL NEOPLASMS; HSP90 HEAT-SHOCK PROTEINS; HUMANS; LACTAMS, MACROCYCLIC; NAD(P)H DEHYDROGENASE (QUINONE); PATIENT SELECTION; PHARMACOGENETICS; POLYMORPHISM, SINGLE NUCLEOTIDE; RNA, MESSENGER; TIME FACTORS; TRANSFECTION; TUMOR MARKERS, BIOLOGICAL;

EID: 84901406295     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-14-334     Document Type: Article

References (18)

1. Patki JM, Pawar SS. HSP90: Chaperone-me-not. Pathol Oncol Res 2013, 19:631-640. 10.1007/s12253-013-9675-4, 23900891.
2. Wu X, Wanders A, Wardega P, Tinge B, Gedda L, Bergstrom S, Sooman L, Gullbo J, Bergqvist M, Hesselius P, Lennartsson J, Ekman S. Hsp90 is expressed and represents a therapeutic target in human oesophageal cancer using the inhibitor 17-allylamino-17-demethoxygeldanamycin. Br J Cancer 2009, 100:334-343. 10.1038/sj.bjc.6604855, 2634703, 19142186.
3. Neckers L, Workman P. Hsp90 molecular chaperone inhibitors: are we there yet?. Clin Cancer Res 2012, 18:64-76. 10.1158/1078-0432.CCR-11-1000, 3252205, 22215907.
4. Samuni Y, Ishii H, Hyodo F, Samuni U, Krishna MC, Goldstein S, Mitchell JB. Reactive oxygen species mediate hepatotoxicity induced by the Hsp90 inhibitor geldanamycin and its analogs. Free Radic Biol Med 2010, 48:1559-1563. 10.1016/j.freeradbiomed.2010.03.001, 2862863, 20211249.
5. Guo W, Reigan P, Siegel D, Zirrolli J, Gustafson D, Ross D. The bioreduction of a series of benzoquinone ansamycins by NAD (P) H:quinone oxidoreductase 1 to more potent heat shock protein 90 inhibitors, the hydroquinone ansamycins. Mol Pharmacol 2006, 70:1194-1203. 10.1124/mol.106.025643, 16825487.
6. Siegel D, Shieh B, Yan C, Kepa JK, Ross D. Role for NAD (P) H:quinone oxidoreductase 1 and manganese-dependent superoxide dismutase in 17-(allylamino)-17-demethoxygeldanamycin-induced heat shock protein 90 inhibition in pancreatic cancer cells. J Pharmacol Exp Ther 2011, 336:874-880. 10.1124/jpet.110.176438, 3061536, 21156818.
7. Traver RD, Horikoshi T, Danenberg KD, Stadlbauer THW, Danenberg PV, Ross D, Gibson NW. NAD (P) H:Quinone Oxidoreductase Gene Expression in Human Colon Carcinoma Cells: Characterization of a Mutation Which Modulates DT-Diaphorase Activity and Mitomycin Sensitivity. Cancer Res 1992, 52:797-802.
8. Siegel D, Anwar A, Winski SL, Kepa JK, Zolman KL, Ross D. Rapid polyubiquitination and proteasomal degradation of a mutant form of NAD (P) H:quinone oxidoreductase 1. Mol Pharmacol 2001, 59:263-268.
9. Veale RB, Thornley AL. Increased single class low affinity EGF receptors expressed by human esophageal squamous carcinoma cell lines. S Afr J Sci 1989, 85:375-379.
10. Asher G, Lotem J, Cohen B, Sachs L, Shaul Y. Regulation of p53 stability and p53-dependent apoptosis by NADH quinone oxidoreductase 1. Proc Natl Acad Sci U S A 2001, 98:1188-1193. 10.1073/pnas.98.3.1188, 14730, 11158615.
11. Akkiz H, Bayram S, Bekar A, Akgöllü E, Ülger Y, Kaya BY, Sandikçi M, Özdil B. No association of NAD (P) H: quinone oxidoreductase 1 (NQO1) C609T polymorphism and risk of hepatocellular carcinoma development in Turkish subjects. Asian Pac J Cancer Prev 2010, 11:1051-1058.
12. Prodromou C. Strategies for stalling malignancy: targeting cancer's addiction to Hsp90. Curr Top Med Chem 2009, 9:1352-1368. 10.2174/156802609789895656, 19860736.
13. Saif MW, Erlichman C, Dragovich T, Mendelson D, Toft D, Burrows F, Storgard C, Von Hoff D. Open-label, dose-escalation, safety, pharmacokinetic, and pharmacodynamic study of intravenously administered CNF1010 (17-(allylamino)-17-demethoxygeldanamycin [17-AAG]) in patients with solid tumors. Cancer Chemother Pharmacol 2013, 71:1345-1355. 10.1007/s00280-013-2134-9, 23564374.
14. Tang Z, Wu M, Li Y, Zheng X, Liu H, Cheng X, Xu L, Wang G, Hao H. Absolute quantification of NAD (P) H:quinone oxidoreductase 1 in human tumor cell lines and tissues by liquid chromatography-mass spectrometry/mass spectrometry using both isotopic and non-isotopic internal standards. Anal Chim Acta 2013, 772:59-67.
15. Karkoulis PK, Stravopodis DJ, Konstantakou EG, Voutsinas GE. Targeted inhibition of heat shock protein 90 disrupts multiple oncogenic signaling pathways, thus inducing cell cycle arrest and programmed cell death in human urinary bladder cancer cell lines. Cancer Cell Int 2013, 13:11. 10.1186/1475-2867-13-11, 3583703, 23394616.
16. Gaspar N, Sharp SY, Pacey S, Jones C, Walton M, Vassal G, Eccles S, Pearson A, Workman P. Acquired resistance to 17-allylamino-17-demethoxygeldanamycin (17-AAG, tanespimycin) in glioblastoma cells. Cancer Res 2009, 69:1966-1975. 10.1158/0008-5472.CAN-08-3131, 2652695, 19244114.
17. Moscovitz O, Tsvetkov P, Hazan N, Michaelevski I, Keisar H, Ben-Nissan G, Shaul Y, Sharon M. A mutually inhibitory feedback loop between the 20S proteasome and its regulator, NQO1. Mol Cell 2012, 47:76-86.
18. Siegel D, Yan C, Ross D. NAD (P) H:quinone oxidoreductase 1 (NQO1) in the sensitivity and resistance to antitumor quinones. Biochem Pharmacol 2012, 83:1033-1040. 10.1016/j.bcp.2011.12.017, 3482497, 22209713.